Anika Therapeutics | ANIK - Assets


Anika Therapeutics reported $179.39M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Agenus USD 186.46M 40.34M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Integra LifeSciences USD 3.58B 24.28M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merit Medical Systems USD 2.72B 33.36M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Smith & Nephew USD 10.69B 150M Dec/2025
Stryker USD 46.29B 1.55B Mar/2026
Surmodics USD 169.82M 8.74M Jun/2025
Veracyte USD 1.44B 30.38M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026
Zimmer Biomet Holdings USD 22.72B 370.1M Mar/2026